In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Ideaya Biosciences Inc (NASDAQ: IDYA) closed at $29.47 in the last session, down -3.35% from day before closing price of $30.49. In other words, the price has decreased by -$3.35 from its previous closing price. On the day, 0.69 million shares were traded. IDYA stock price reached its highest trading level at $30.52 during the session, while it also had its lowest trading level at $29.31.
Ratios:
We take a closer look at IDYA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 22.93 and its Current Ratio is at 22.93. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $50.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 26 ’24 when Jason Throne bought 75,000 shares for $40.22 per share.
WHITE MICHAEL ANTHONY sold 28,500 shares of IDYA for $1,032,884 on May 29 ’24. The Chief Scientific Officer now owns 0 shares after completing the transaction at $36.24 per share. On May 15 ’24, another insider, Hata Yujiro S, who serves as the President and CEO of the company, sold 83,856 shares for $42.90 each. As a result, the insider received 3,597,756 and left with 677,887 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IDYA now has a Market Capitalization of 2547144960 and an Enterprise Value of 1645912064. For the stock, the TTM Price-to-Sale (P/S) ratio is 649.78 while its Price-to-Book (P/B) ratio in mrq is 2.16. Its current Enterprise Value per Revenue stands at 419.661 whereas that against EBITDA is -7.404.
Stock Price History:
Over the past 52 weeks, IDYA has reached a high of $47.74, while it has fallen to a 52-week low of $27.52. The 50-Day Moving Average of the stock is -6.78%, while the 200-Day Moving Average is calculated to be -23.55%.
Shares Statistics:
According to the various share statistics, IDYA traded on average about 707.68K shares per day over the past 3-months and 778080 shares per day over the past 10 days. A total of 86.43M shares are outstanding, with a floating share count of 78.33M. Insiders hold about 9.37% of the company’s shares, while institutions hold 95.26% stake in the company. Shares short for IDYA as of 1730332800 were 9306160 with a Short Ratio of 13.15, compared to 1727654400 on 12075624. Therefore, it implies a Short% of Shares Outstanding of 9306160 and a Short% of Float of 12.01.
Earnings Estimates
The dynamic stock of Ideaya Biosciences Inc (IDYA) is currently being evaluated by a team of 11.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.46 and low estimates of -$0.84.
Analysts are recommending an EPS of between -$1.58 and -$2.53 for the fiscal current year, implying an average EPS of -$2.37. EPS for the following year is -$2.66, with 11.0 analysts recommending between -$2.11 and -$3.49.
